PREEMPTIVE RITUXIMAB TREATMENT MAY REDUCE THE INCIDENCE OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (PTLD) IN PATIENTS WITH EBV REACTIVATION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

被引：1
|
作者：
Kindwall-Keller, T. L. [1 ]
Cooper, B. W. [1 ]
Laughlin, M. J. [1 ]
Gerson, S. L. [1 ]
Barr, P. [1 ]
Erinc, S. [1 ]
Creger, R. J. [1 ]
Lazarus, H. M. [1 ]
机构：
[1] Univ Hosp Cleveland, Case Med Ctr, Cleveland, OH 44106 USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2009年 / 15卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2008.12.282
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
250
引用
收藏
页码：91 / 91
页数：1
相关论文
共 50 条
  • [41] Treatment Patterns for Patients with Post-Transplant Lymphoproliferative Disorder Who Fail Rituximab after Allogeneic Hematopoietic Stem Cell Transplantation: Findings from a Systematic Literature Review
    Xu, Hairong
    Watson, Crystal
    Garib, Shan Ashton
    Forsythe, Anna
    Barlev, Arie
    BLOOD, 2018, 132
  • [42] Post-Transplant Lymphoproliferative Disorders (PTLD) after renal transplantation in the Republic of Ireland: A 20 year review
    Prendeville, S.
    O'Regan, J.
    Power, C.
    Deady, S.
    Williams, Y.
    O' Kelly, P.
    Comber, H.
    Conlon, P.
    Leader, M.
    VIRCHOWS ARCHIV, 2012, 461 : S21 - S22
  • [43] Use of low dose Rituximab for treatment of EBV reactivation post allogeneic stem cell transplant: A single centre experience
    Publicover, A.
    Prichard, M.
    Richardson, D. S.
    Hill, K.
    Hurlock, C.
    Jarvis, L.
    Launders, H.
    Main, S.
    McKeagl, N.
    Newman, J.
    Orchard, K. H.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S189 - S189
  • [44] Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation
    Frank Lieberman
    Victor Yazbeck
    Anastasios Raptis
    Raymond Felgar
    Michael Boyiadzis
    Journal of Neuro-Oncology, 2012, 107 : 225 - 232
  • [45] Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation
    Lieberman, Frank
    Yazbeck, Victor
    Raptis, Anastasios
    Felgar, Raymond
    Boyiadzis, Michael
    JOURNAL OF NEURO-ONCOLOGY, 2012, 107 (02) : 225 - 232
  • [46] First-line treatment with rituximab improves survival of patients with post-transplant lymphoproliferative disease (PTLD).
    Gonzalez-Barca, E
    Domingo-Domenech, E
    Gomez-Codina, J
    Capote, F
    Flores, E
    Briones, J
    Salar, A
    Panizo, C
    Montalban, C
    Ribera, JM
    Caballero, D
    Muñoz, A
    Gallur, L
    Canales, MA
    Fernandez, P
    Encuentra, M
    de Sevilla, AF
    BLOOD, 2004, 104 (11) : 394A - 394A
  • [47] The Management of EBV-Associated Post-Transplant Lymphoproliferative Disorder with Central Nervous System Involvement After Allogeneic Hematopoietic Stem Cell Transplantation
    Wu, Meiqing
    Zhang, Yu
    Huang, Fen
    Zhou, Hongsheng
    Fan, Zhiping
    Yu, Guopan
    Guo, Xutao
    Zhang, Xian
    Feng, Ru
    Sun, Jing
    Liu, Qifa
    BLOOD, 2012, 120 (21)
  • [48] THE MANAGEMENTS OF EBV-ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Wu, M.
    Sun, J.
    Zhang, Y.
    Huang, F.
    Zhou, H.
    Fan, Z.
    Xuan, L.
    Yu, G.
    Guo, X.
    Zhang, X.
    Liu, C.
    Dai, M.
    Feng, R.
    Liu, Q.
    HAEMATOLOGICA, 2013, 98 : 372 - 372
  • [49] Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation
    Cook, RC
    Connors, JM
    Gascoyne, RD
    Fradet, G
    Levy, RD
    LANCET, 1999, 354 (9191): : 1698 - 1699
  • [50] Successful treatment of 2 patients with B-cell post-transplant lymphoproliferative disorders with rituximab.
    Riggs, SA
    Radovancevic, B
    Massin, EK
    Radovancevic, R
    Bracey, AW
    Heslop, HE
    Cabanillas, F
    Frazier, OH
    BLOOD, 2000, 96 (11) : 246B - 246B
12345